• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Ticagrelor or Clopidogrel as Antiplatelet Agents in Patients with Chronic Kidney Disease and Cardiovascular Disease: A Meta-analysis
ConclusionsWhen compared with clopidogrel, even though ticagrelor was not associated with higher risk of adverse cardiovascular outcomes in these patients with CKD, it was associated with significantly higher BARC bleeding. Therefore, the safety outcomes of ticagrelor still require further evaluation in patients with CKD. Nevertheless, this hypothesis should only be confirmed with more powerful results that could usually only be achieved using large-scale randomized trials.
Source: American Journal of Cardiovascular Drugs - August 2, 2023 Category: Cardiology Source Type: research

Differential Impact of Clinical Factors for Predicting High Platelet Reactivity on Clinical Outcomes in Acute Myocardial Infarction Patients Treated With Clopidogrel and Prasugrel
CONCLUSIONS: Clinical factors listed in the HHD-GENE score may help stratify ischemic risks in patients with acute MI treated with clopidogrel and prasugrel, whereas risk stratification without genetic testing in patients treated with clopidogrel may be challenging.PMID:37316266 | DOI:10.5551/jat.64217
Source: Journal of Atherosclerosis and Thrombosis - June 14, 2023 Category: Cardiology Authors: Hiroki Goto Yuichi Saito Tadahiro Matsumoto Takanori Sato Daichi Yamashita Sakuramaru Suzuki Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research

Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III
CONCLUSIONS: This integrated analysis supports the findings of PRASTRO-III. Prasugrel is a promising treatment that results in a numerical reduction in the composite incidence of ischemic stroke, MI, and death from other vascular causes in patients with ischemic stroke who are at a high risk of stroke recurrence. No major safety issues were observed for prasugrel.PMID:37011599 | DOI:10.1159/000529149
Source: Atherosclerosis - April 3, 2023 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Toshiaki Shirai Atsushi Takita Takeshi Kuroda Kazumi Kimura Source Type: research

Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances
Kardiol Pol. 2022;80(12):1200-1210. doi: 10.33963/KP.a2022.0283.ABSTRACTAtherosclerotic cardiovascular disease (ASCVD), which includes coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD) is associated with significant morbidity, mortality, and healthcare costs. Antiplatelet therapy has long been the mainstay of antithrombotic therapy for the prevention of first-ever and recurrent ASCVD events. More recently, however, randomized trials have demonstrated the benefits and cost-effectiveness of a dual pathway inhibition (DPI) strategy in acute and chronic ASCVD. When used in combinatio...
Source: Kardiologia Polska - January 5, 2023 Category: Cardiology Authors: Stephanie Carlin Tim Ac de Vries Andrzej Budaj John Eikelboom Source Type: research

Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study
Conclusions Although risks for 1-year MACE were significantly higher in ACS PCI patients with versus without CKD, prasugrel use was 50% lower in patients with renal impairment. Irrespective of CKD status, outcomes associated with prasugrel use were not significant after propensity adjustment. These data highlight the need for randomized studies evaluating the optimal antiplatelet therapy in CKD patients with ACS.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 16, 2017 Category: Cardiology Authors: Baber, U., Chandrasekhar, J., Sartori, S., Aquino, M., Kini, A. S., Kapadia, S., Weintraub, W., Muhlestein, J. B., Vogel, B., Faggioni, M., Farhan, S., Weiss, S., Strauss, C., Toma, C., DeFranco, A., Baker, B. A., Keller, S., Effron, M. B., Henry, T. D., Tags: Coronary Source Type: research

Pages: 1  2